Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH
- Status
- TERMINATED
- Phase
- PHASE4
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
- Status
- TERMINATED
- Phase
- PHASE3
Serological Study of Dengue and Characterization of Immune Response in Ten Endemic and Non-Endemic Cities in Mexico
- Status
- UNKNOWN
- Phase
- NA
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)
- Status
- COMPLETED
- Phase
- PHASE2
Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
- Status
- COMPLETED
- Phase
- PHASE3
Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)
- Status
- COMPLETED
- Phase
- PHASE3
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension
- Status
- COMPLETED
- Phase
- PHASE3
SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy
- Status
- RECRUITING
- Phase
- PHASE2
Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3